Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
By Josh Beckerman Cabaletta Bio shares were down 32% to $12.72 after the U.S. Food and Drug Administration said it is looking into reports of T-cell malignancies in patients who received.